Tufts Center for the Study of Drug Development estimated that an agentic AI clinical monitoring tool from Medable can deliver outsized value in oncology trials, modeling net financial gains up to $21 million per program and ROI up to 82x. The analysis ties the projected benefit to reductions in on-site visits and travel, faster enrollment, and accelerated database lock. The report also quantified speed impacts: agentic AI could accelerate development by roughly 18 weeks overall, with reported reductions of 109 to 119 days in enrollment timelines and shorter closeout activities. The modeling uses eNPV approaches based on benchmarked oncology program data and Medable contract value. Separately, a separate clinical-operations analysis argued for EMT training as mobile staff infrastructure for decentralized trials, aiming to address monitoring and regulatory constraints when care is delivered in community settings. Together, these pieces point to accelerating adoption of trial-execution automation—both for monitoring and for delivering field-based assessments.